

### Journalbeiträge

1. Ritter C, Sehrt D, Jaehde U (2012) Editorial. Approaches to personalized medicine in oncology--the 9th Annual Meeting of CESAR in Greifswald. INT J CLIN PHARM TH, 50(1): 53-4.
2. Saadatmand AR, Tadjerpisheh S, Brockmüller J, Tzvetkov MV (2012) The prototypic pharmacogenetic drug debrisoquine is a substrate of the genetically polymorphic organic cation transporter OCT1. BIOCHEM PHARMACOL, 83(10): 1427-34.
3. Schäfer A, Emmert S, Kruppa J, Schubert S, Tzvetkov M, Mössner R, Reich K, Berking C, Volkenandt M, Pföhler C, Schön MP, Vogt T, König IR, Reichrath J (2012) No association of vitamin D metabolism-related polymorphisms and melanoma risk as well as melanoma prognosis: a case-control study. ARCH DERMATOL RES, 304(5): 353-61.
4. Schirmer MA, Nadine Mergler CP, Rave-Fränk M, Herrmann MK, Hennies S, Gaedcke J, Conradi LC, Jo P, Beissbarth T, Hess CF, Becker H, Ghadimi M, Brockmüller J, Christiansen H, Wolff HA (2012) Acute toxicity of radiochemotherapy in rectal cancer patients: a risk particularly for carriers of the TGFB1 Pro25 variant. INT J RADIAT ONCOL, 83(1): 149-57.
5. Schirmer MA, Wolff HA, Conradi LC, Christiansen H (2012) In regard to "Thymidylate synthase gene polymorphism affects the response to preoperative 5-fluorouracil chemoradiation therapy in patients with rectal cancer" (Int J Radiat Oncol Biol Phys 2011;81:669-676). INT J RADIAT ONCOL, 82(3): 1058.
6. Seegers J, Vos MA, Flevari P, Willems R, Sohns C, Vollmann D, Lüthje L, Kremastinos DT, Floré V, Meine M, Tuinenburg A, Myles RC, Simon D, Brockmüller J, Friede T, Hasenfuß G, Lehnart SE, Zabel M, for the EUTrigTreat Clinical Study Investigators (2012) Rationale, objectives, and design of the EUTrigTreat clinical study: a prospective observational study for arrhythmia risk stratification and assessment of interrelationships among repolarization markers and genotype. EUROPACE, 14(3): 416-22.
7. Tzvetkov MV, Saadatmand AR, Bokelmann K, Meineke I, Kaiser R, Brockmüller J (2012) Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT(3) antagonists tropisetron and ondansetron. PHARMACOGENOMICS J, 12(1): 22-9.
8. Tzvetkov M, von Ahsen N (2012) Pharmacogenetic screening for drug therapy: from single gene markers to decision making in the next generation sequencing era. PATHOLOGY, 44(2): 166-80.
9. Vormfelde SV, Brockmüller J (2012) The genetics of loop diuretic effects. PHARMACOGENOMICS J, 12(1): 45-53.

### Habilitationen

1. Tzvetkov M (2012) Functional and clinical relevance of genetic polymorphisms in the organic cation transporters OCT1 and OCT2. Habilitation Universität Göttingen.
2. Tzvetkov M (2012) Functional and clinical relevance of genetic polymorphisms in the organic cation transporters OCT1 and OCT2. Habilitation Universität Göttingen.

### Medizinische Dissertationen

1. Kuschel C, Dr. med. (2012) Funktionelle und genetische Variabilität bei der zytotoxischen Wirkung von Nukleosid-Analoga - Untersuchung in menschlichen Leukozyten und lymphoblastoiden Zelllinien. Dissertation Universität Göttingen.
2. Torno E, Dr. med. (2012) Bedeutung genetischer Polymorphismen in den Genen des Transportproteins SLC6A14, des Leptinrezeptors, des Adiponektins und des Adiponektin-Rezeptors für das Risiko, unter Antipsychotikatherapie Übergewicht zu erleiden. Dissertation Universität Göttingen.
3. Wissmüller E, Dr. med. (2012) Zum Langzeitverlauf und zur Mortalität von Benzodiazepinabhängigen im Vergleich zu Kontrollen. Dissertation Universität Göttingen.

### Naturwiss. u.a. nichtmed. Diss.

1. Saadatmand AR, Dr. rer. nat. (2012) Simulation and Analysis of Epistatic Interactions between Xenobiotics Membrane Transporters and Metabolizing Enzymes on Biotransformation, Pharmacodynamics and Toxic Effects of Drugs and Carcinogens. Dissertation Universität Göttingen.